Obesity – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of obesity / overweight comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of obesity / overweight for each country, as well as annualized case counts projected to the national population.
Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s obesity / overweight forecast will answer the following questions:
- Of all people with obesity / overweight, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of obesity / overweight over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts 17 obesity / overweight patient populations:
- Total prevalent cases of obesity
- Total prevalent cases of class I obesity
- Total prevalent cases of class II obesity
- Total prevalent cases of class III obesity
- Total prevalent cases of overweight
- Total prevalent cases of obesity after effective usage of GLP-1 RAs
- Total drug-eligible prevalent cases of overweight
- Total prevalent cases of non-drug-eligible overweight
- Diagnosed drug-treated prevalent cases of obesity
- Diagnosed non-drug-treated prevalent cases of obesity
- Diagnosed prevalent cases of obesity with hypertension
- Diagnosed prevalent cases of obesity with type 2 diabetes
- Diagnosed prevalent cases of obesity
- Undiagnosed prevalent cases of obesity
- Diagnosed drug-eligible prevalent cases of overweight
- Drug-treated prevalent cases of overweight
- Non-drug-treated prevalent cases of overweight
Note: Coverage may vary by country.
Table of contents
- Obesity - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in / excluded from the analyses of obesity / overweight)
- Total obesity / overweight prevalent cases
- Severity of obesity
- Total obesity prevalent cases after effective usage of GLP-1 RAs
- Diagnosed obesity / drug-eligible overweight prevalent cases
- Total drug-eligible overweight prevalent cases
- Diagnosed obesity / drug-eligible overweight drug-treated prevalent cases
- Diagnosed obesity prevalent cases with type 2 diabetes
- Diagnosed obesity prevalent cases with hypertension
- Risk / protective factors applied to disease forecast models
- Reference materials
